USFDA Guidance: Individualized Human Genome Editing Products and Q&A on QT/QTc Safety Evaluation
The US FDA has issued two important regulatory documents addressing emerging approaches in gene-editing product development and the evaluation of drug-induced QT/QTc prolongation. The first focuses on individualized human genome-editing products, while the second updates the ICH E14/S7B recommendations for assessing cardiac safety.
The FDA's October 2026 draft guidance provides recommendations for developing and regulating individualized human genome-editing products intended to treat monogenic diseases caused by known pathogenic genetic variants.
Multiple Variants Within a Single BLA
The guidance describes an approach that may allow multiple individualized product variants to be included in one Biologics License Application (BLA) under section 351(a) of the Public Health Service Act.
Sponsors should define an Individualized Feature Space (IFS), establishing acceptable boundaries for product variation while maintaining consistent fundamental product characteristics, such as the mechanism of action and intended editing outcome.
Manufacturing and Quality Considerations
Manufacturing controls should address the specific genome-editing technology used. Relevant considerations include editing efficiency, product consistency, impurities, cell viability, delivery systems and manufacturing process performance.
Sponsors should establish appropriate potency assays, process validation and ongoing monitoring to demonstrate product quality and consistency across variants.
Safety and Post-Approval Changes
Safety assessments should consider unintended on-target and off-target editing, genomic alterations, immunogenicity and other relevant risks. Appropriate analytical methods, including next-generation sequencing, may support these evaluations.
After approval, additional variants within the established IFS may be introduced through a BLA supplement, supported by appropriate in-vitro data and updated manufacturing information. FDA recommends considering a Post-Approval Change Management Protocol (PACMP) to facilitate future changes.
Labelling and Identification
Product labelling should clearly identify the approved disease and relevant genetic variant or variant class. Appropriate product and patient-specific identification should also be considered.
On October 30, 2026, the FDA issued the final ICH E14/S7B Questions and Answers (R1) guidance, providing updated recommendations for evaluating the potential of drugs to cause QT/QTc prolongation and proarrhythmic effects.
Clinical Evaluation – E14
The guidance clarifies ECG assessment, study design, heart-rate correction and concentration-QTc analysis.
Sponsors should use validated ECG methods, trained readers and consistent measurement approaches to minimise variability. Fridericia correction is commonly appropriate, while other correction methods may be justified depending on the drug and study context.
Concentration-response modelling can support QT/QTc assessment, provided the methodology, assumptions and model-selection criteria are appropriately established.
Nonclinical Evaluation – S7B
The guidance reinforces an integrated assessment using in-vitro, in-vivo and clinical evidence to evaluate potential proarrhythmic risk.
The extent of testing should reflect the likelihood of interaction with cardiac ion channels, including hERG. In-vitro studies should use appropriate experimental conditions and assess relevant cardiac ion channels. In-vivo studies should provide adequate exposure and ECG evaluation.
Alternative approaches, including qualified in-silico and experimental models, may contribute to the overall assessment when their applicability and limitations are adequately justified.
Integrated Risk Assessment
Sponsors should consider the totality of evidence rather than relying on a single test result. This includes nonclinical findings, QT/QTc changes, drug exposure, metabolites and relevant clinical observations.
The updated recommendations also support incorporating suitable QT assessments into general toxicology studies where scientifically justified, potentially reducing the need for separate studies.
Comments